• Über Taylor Wessing
  • Unsere Anwälte
  • Expertise
    • Branchen
        • Technologie-, Medien & Kommunikation
        • Private Wealth
        • Real Estate, Infrastructure & Energy
        • Life Sciences & Healthcare
        • Aerospace & Defence
        • Automobilindustrie & Mobilität
        • Business & Professional Services
        • Chemieindustrie
        • Konsumgüter und Einzelhandel
        • Bank- & Finanzwesen
        • Hotels, Hospitality & Leisure
        • Logistik & Transport
        • Industrieunternehmen
        • Öffentliche Dienste & Bildungsinfrastruktur
    • Rechtsgebiete
        • Künstliche Intelligenz
        • Bank- & Finanzrecht
        • Marken & Werbung
        • Handels- & Vertriebsrecht
        • Kartell-, Vergabe-, Beihilfe- und Außenhandelsrecht
        • Urheber- und Medienrecht
        • Wirtschaftsstrafrecht und Compliance
        • M&A / Gesellschaftsrecht & Kapitalmarktrecht
        • Daten & Cybersicherheit
        • Disputes & Investigations
        • Arbeitsrecht
        • Umwelt, Planung & Regulierung
        • Environmental, Social & Governance (ESG)
        • Informationstechnologie
        • Notariat & Geschäftsgeheimnisse
        • Patents Technology & Life Sciences
        • Private Client
        • Private Equity
        • Projects, Energy & Infrastructure
        • Immobilienrecht
        • Regulation
        • Restrukturierung & Insolvenzrecht
        • Steuerrecht
        • Venture Capital
  • International
    • Europa
        • Standorte
        • Österreich
        • Belgien
        • Tschechische Republik
        • Frankreich
        • Deutschland
        • Ungarn
        • Italy
        • Niederlande
        • Polen
        • Portugal
        • Republik Irland
        • Slowakei
        • Spanien
        • Großbritannien
        • Ukraine
          Groups & regions
        • CEE Turkish Desk
        • French German Group
        • Unsere Büros
    • Naher Osten & Afrika
        • Standorte
        • Naher Osten
        • Vereinigte Arabische Emirate
          Groups
        • Africa Group
        • Israel Group
        • Unsere Büros
    • Amerika
        • Standorte
        • Latein Amerika
        • USA
          Groups
        • Brazil Group
        • Unsere Büros
    • Asien
        • Standorte
        • Asien
        • China
        • Südkorea
          Groups
        • India Group
        • Japan Group
        • Unsere Büros
  • Insights
    • Insights
        • Featured Topics
        • Artificial intelligence
        • Data Centre Expertise
        • EU-Whistleblower-Richtlinie (HinSchG)
        • Lieferkettengesetz
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: Digitales Tech-Magazin
        • Podcasts
        • Synapse
        • Alle Insights
    • Events
        • In Präsenz
        • Online
        • Alle Events
    • News
        • Media Center
        • Unternehmensmeldungen
        • Deal Meldungen
        • Alle News
  • Karriere
  • DE
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • Team
  • Carlemi Calitz
Dr. Carlemi Calitz
Dr. Carlemi Calitz

Dr. Carlemi Calitz

EPG Beraterin

  • Eindhoven Niederlande
+31 88 0243 001
vCard
E-Mail Call me

Carlemi is a UPC legal officer and patent advisor  of the Intellectual Property practice group.

She brings a uniquely multidisciplinary perspective to the Patents and Innovation team, combining over a decade of cutting-edge scientific research with a growing legal expertise. As a UPC Legal Officer with a focus on patent advisory, she draws on her extensive background in pharmaceutics, biochemistry, and advanced biomimetic modeling to support clients at the intersection of science, technology, and intellectual property.

With 27 peer-reviewed publications and experience in managing EU-funded innovation projects, she is adept at navigating complex scientific and regulatory landscapes—an asset in evaluating patentability, supporting IP strategy, and communicating effectively with inventors and examiners.

Expertise

Rechtsgebiete und Gruppen

Patents Technology & Life Sciences

Branchen

Life Sciences & Healthcare

CV

Since 2025 UPC Legal Officer, Taylor Wessing
2021-2025 Postdoctoral Research Fellow GUTVIBRATIONS consortium, Amsterdam UMC
2018-2021 Postdoctoral Research Fellow, Uppsala University, Sweden
2018-2021 Postdoctoral Research Fellow, North west University, South Africa
2017 PhD Pharmaceutics, North west University
2014 MSc Pharmaceutics, North-west University
2011 Hons. BSc Biochemistry and Physiology, North-west University
2010 BSc Biochemistry and Physiology, North-west University

Karriere

Since 2025 UPC Legal Officer, Taylor Wessing
2021-2025 Postdoctoral Research Fellow GUTVIBRATIONS consortium, Amsterdam UMC
2018-2021 Postdoctoral Research Fellow, Uppsala University, Sweden
2018-2021 Postdoctoral Research Fellow, North west University, South Africa

Ausbildung

2017 PhD Pharmaceutics, North west University
2014 MSc Pharmaceutics, North-west University
2011 Hons. BSc Biochemistry and Physiology, North-west University
2010 BSc Biochemistry and Physiology, North-west University

Publikationen

  • Effect of antivirals on clinical and lab-adapted human cytomegalovirus strains using induced Pluripotent Stem Cell-derived human neural models. 2025. L Mulder, R Vieira da Sá, J Korsten, E Freeze, G Koen, R Molenkamp, J Van Kampen, M Cornelissen, F Zorgdrager, KC Wolthers, D Pajkrt, A Sridhar and C Calitz. Submitted to Antiviral Research. 
  • Towards personalized medicine: the effect of treatment of chronic enterovirus diarrhea in an immunocompromised patient and the correlation with in vitro models. 2024. G Moreni, C Calitz, G Koen, H van Eijk, N Johannesson, J De Ruijter, K S M Benschop, J Cremer, D Pajkrt, A Sridhar, E J Peters, and K C Wolthers. Submitted to Open Forum Infectious Diseases (Under review) 
  • A Human Biomimetic Intestinal Mucosa Model to Study Gastrointestinal Development and Disease. 2024. A Dei*, C Calitz*, J Korsten, N Johannesson, E Freeze, A Eaves, S Louis, R.K. Conder, W Chang, D Pajkrt, K.C. Wolthers, A Sridhar, S Simmini. Submitted to Nature Communications. https://doi.org/10.1101/2024.08.20.608742 *Shared first authorship 
  • Parechovirus infection in human brain organoids: host innate inflammatory response and not neuro-infectivity correlates to neurologic disease. 2024. P Capendale, I García-Rodríguez, AT Ambikan, L Mulder, J Depla, E Freeze, G Koen, C Calitz, V Sood, R Vieira de Sá, U Neogi, D Pajkrt, A Sridhar and K Wolthers. Nature Communications 15(1):2532. 10.1038/s41467-024-46634-9. 
  • The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. 2024. Ianevski A, Frøysa, IT, Lysvand, H, Calitz, C, Smura, T, Schjelderup Nilsen, H.-J, Høyer, E, Afset, JE, Sridhar, A, Wolthers, KC, Zusinaite, E, Tenson, T, Kurg, R, Oksenych, V, Galabov, AS, Stoyanova, A, Bjørås, M and Kainov, DE. Antiviral Research.  https://doi.org/10.1016/j.antiviral.2024.105842  
  • Assessment of The Broad-Spectrum Host Targeting Antiviral Efficacy of Halofuginone Hydrobromide in Human Airway, Intestinal and Brain Organoid Models. 2024. I García-Rodríguez, G Moreni, P.E Capendale, I Aknouch, L Mulder, R Vieira de Sá, N Johannesson, E Freeze, H van Eijk, G Koen, K.C Wolthers, D Pajkrt, A Sridhar and C Calitz Antiviral Research https://doi.org/10.1016/j.antiviral.2024.105798 *Shared last authorship 
  • Non-Polio Enterovirus C Replicate in Both Airway and Intestine Organotypic Cultures. 2023 
    G Moreni, H van Eijk, G Koen, N Johannesson, C Calitz, K Benschop, J Cremer, D Pajkrt, A Sridhar and K Wolthers Viruses 15(9):1823 
  • Amino acid variation at VP1-145 of enterovirus A71 determines the viral infectivity and receptor usage in a primary human intestinal model. 2023. I Aknouch, I García-Rodríguez, F.P Giugliano, C Calitz, G Koen, H van Eijk, N Johannessson, S Rebers, L Brouwer, V Muncan, KJ Stittelaar, D Pajkrt, K.C Wolthers and A Sridhar Frontiers in Microbiology 14:1045587 
  • Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma. 2023. C Calitz, J Rosenquist, O Degerstedt, J Khaled, M Kopsida, M Fryknäs, H Lennernäs, A Samanta, F Heindryckx. Scientific Reports 13(1):748 
  • Human milk inhibits some enveloped virus infections, including SARS-CoV-2, in an intestinal model. 2022. Aknouch, I., Sridhar, A., Freeze, E., Giugliano, F.P., van Keulen, B.J., Romijn, M., Calitz, C., García-Rodríguez, I., Mulder,L., Wildenberg, M.E., Muncan, V., van Gils, M.J., van Goudoever, J.B., Stittelaar, K.J., Wolthers, K.C and Pajkrt, D. Life science alliance., 5(12): e202201432 
  • Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model. 2022.  C Calitz, J Khaled, J Rosenquist, M Kopsida, O Degerstedt, H Lennernas, M Fryknäs, A Samanta and F Heindryckx. Journal of Hepatology., 77:s368 
     
    Bridging the gap between emerging models and humans by learning from polio animal studies: A systematic review. 2022.  G Moreni, I Aknouch, M Ras, L Brouwer, R Spijker, C Calitz, KJ Stittelaar, A Sridhar, KC Wolthers, D Pajkrt. Clinical and Translational Discovery., 2(2):e42 
  • In vitro cell toxicity and intracellular uptake of doxorubicin exposed as a solution or liposomes: Implications for treatment of hepatocellular carcinoma. 2021. F Kullenberg, O Degerstedt, C Calitz, N Pavlović, D Balgoma, J Gråsjö, E Sjögren, M Hedeland, F Heindryckx, H Lennernäs. Cells., 10(7):1717 
  • Anthracyclins increase PUFAs: potential implications in ER stress and cell death. 2021. 
    D Balgoma, F Kullenberg, C Calitz, M Kopsida, F Heindryckx, H Lennernäs, M Hedeland. Cells., 10(5):1163
  • Clinostat 3D cell culture – protocols for the preparation and functional analysis of highly reproducible, large, uniform spheroids and organoids. 2021. K Wrzesinski, H Sedighi-Frandsen, C Calitz, C Gouws, B Korzeniowska, SJ. Fey.  Next Generation Culture Platforms for Reliable In Vitro Models: Methods and Protocols, Chapter 2: 17-62 
  • Anticancer Potential of Sutherlandia frutescens and Xysmalobium undulatum in LS180 Colorectal Cancer Mini-Tumors. 2021. C Gouws, T Smit, C Willers, H Svitina, C Calitz, K Wrzesinski. Molecules 26(3):605 
  • Inhibiting endoplasmic reticulum stress decreases tumor burden in a mouse model for hepatocellular carcinoma. 2020. N Pavlovic, C Calitz, K Thanapirom, G Mazza, K Rombouts, P Gerwins, F Heindryckx. eLife, 9, e55865 
  • A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D. 2020. C Calitz, N Pavlovic, J Rosenquist, C Zagami, A Samanta, F Heindryckx. J. Vis. Exp. (162), e61606 
  • Characterization of an alginate encapsulated LS180 spheroid model for anti-colorectal cancer compound screening. 2020. T Smit, C Calitz, C Willers, H Svitina, J Hamman, SJ Fey, C Gouws, K Wrzesinski. ACS Medicinal Chemistry Letters 11 (5), 1014-1021 
  • Fibrin fragment E potentiates TGF-β-induced myofibroblast activation and recruitment. 2020. PÖ Fuchs, C Calitz, N Pavlović, F Binet, SMØ Solbak, UH Danielson, J Kreuger, F Heindryckx, P Gerwins. Cellular Signalling, 109661
  • A sub-chronic Xysmalobium undulatum hepatotoxicity investigation in HepG2/C3A spheroid cultures compared to an in vivo model. 2019.  C Calitz, JH Hamman, SJ Fey, AM Viljoen, C Gouws, K Wrzesinski. Journal of Ethnopharmacology 239, 111897  
  • Toxicity and anti-prolific properties of Xysmalobium undulatum water extract during short-term exposure to two-dimensional and three-dimensional spheroid cell. 2018. C Calitz, JH Hamman, AM Viljoen, SJ Fey, K Wrzesinski, C Gouws Toxicology mechanisms and methods 28 (9), 641-652  
  • Recent Advances in Three-Dimensional Cell Culturing to Assess Liver Function and Dysfunction: From a Drug Biotransformation and Toxicity Perspective. 2018. C Calitz, JH Hamman, SJ Fey, K Wrzesinski, C Gouws Toxicology Mechanisms and Methods, 1-17  
  • Cell-free DNA in a three-dimensional spheroid cell culture model: A preliminary study. 2017.  
    C Calitz*, J Aucamp*, AJ Bronkhorst, K Wrzesinski, S Hamman, C Gouws. The international journal of biochemistry & cell biology 89, 182-192 *Shared first authorship 
  • Herb-drug pharmacokinetic interactions: transport and metabolism of indinavir in the presence of selected herbal products. 2015. C Calitz, C Gouws, J Viljoen, J Steenekamp, L Wiesner, E Abay. Molecules 20 (12), 22113-22127  
  • Herbal hepatotoxicity: current status, examples, and challenges. 2015. C Calitz, L Du Plessis, C Gouws, D Steyn, J Steenekamp, C Muller. Expert opinion on drug metabolism & toxicology 11 (10), 1551-1565  
  • Impact of traditional African medicine on drug metabolism and transport. 2014. C Calitz, JH Steenekamp, JD Steyn, C Gouws, JM Viljoen, JH Hamman Expert opinion on drug metabolism & toxicology 10 (7), 991-1003   
     

Mitgliedschaften

The Pharmaceutical society of South Africa PSSA

Fremdsprachen

English Afrikaans Dutch

Aktuelle News & Insights

Life Sciences & Healthcare

Update aus Berlin: Bundesregierung verschärft Kurs in der Cannabispolitik

5. November 2025
Briefing

von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Martin Jäger

Klicken Sie hier für Details
Patents Technology & Life Sciences

Preliminary injunctions in Poland

5. November 2025
Briefing

von Bartosz Świdrak und Karolina Ciąglewicz

Klicken Sie hier für Details
Deutschland

JUVE Handbuch Wirtschaftskanzleien 2025/26: Taylor Wessing Deutschland bestätigt erneut 5-Sterne-Bewertungen

4. November 2025

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Biotechnologie als Sicherheitsfrage: Warum Dual-Use-Kontrolle und lernende Regulierung über nationale Zukunftsfähigkeit entscheiden

3. November 2025
Quick read

von Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

Klicken Sie hier für Details
Life Sciences & Healthcare

Apothekenreform 2025 – Geplante Änderungen im Überblick

29. Oktober 2025
Briefing

von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Lisa Rottmann, LL.M. (Medizinrecht)

Klicken Sie hier für Details
Patents Technology & Life Sciences

Preliminary injunctions in Belgium

29. Oktober 2025
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Healthcare unlimited – Telemedizin vor dem Durchbruch?

23. Oktober 2025
In-depth analysis

von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Katharina Häberle

Klicken Sie hier für Details
Patents Technology & Life Sciences

Preliminary injunctions in France

22. Oktober 2025
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Advertising skinny jabs – regulators react

15. Oktober 2025
Quick read

von Alison Dennis und Alice Matthews

Klicken Sie hier für Details
Patents Technology & Life Sciences

Preliminary injunctions in Austria

15. Oktober 2025
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Mehr

Weitere Beraterinnen und Berater

Niederlande
Wim Maas

Dr. Wim Maas

Partner

Eindhoven
Amsterdam
+31 6 3175 2962
E-Mail
Profil ansehen
Geert Theuws

Geert Theuws

Counsel

Eindhoven
+31 88 02 43 197
E-Mail
Profil ansehen
David Mulder

David Mulder

Counsel

Amsterdam
+31 88 02 43 019
E-Mail
Profil ansehen
Yingyi Liu

Yingyi Liu

EPG Beraterin

Amsterdam
Eindhoven
+31 88 02 43 086
E-Mail
Profil ansehen
Paula Terzini Leite

Paula Terzini Leite

EPG Beraterin

Eindhoven
+31 88 02 43 282
E-Mail
Profil ansehen
Alle Beraterinnen und Berater

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.

Alle Events
Newsletter-Anmeldung
  • Über Taylor Wessing
  • Campaigns and online tools
  • News
  • Unsere Anwälte
  • Expertise
  • International
  • Insights
  • Events
  • Presse & News
  • Kontakt
  • Karriere
  • Alumni
  • Datenschutzhinweise
  • Datenschutzbestimmungen & Cookie Hinweise
  • Rechtliche und regulatorische informationen
  • Regulatorische Informationen zu Kosten
  • Beschwerdeverfahren für Mandanten
  • Nutzungsbedingungen
  • Anti-slavery Statement
  • Nachhaltigkeit
  • Scam E-Mails

© Taylor Wessing